Granite Point Mortgage Trust Inc. filed a Form 8-K with the SEC on November 4, 2026, announcing its financial results for the fiscal quarter ended September 30, 2026, via an attached press release and earnings call supplemental.
Texas Pacific Land Corporation filed a Form 8-K with the SEC on November 4, 2026, announcing financial results for the three and nine months ended September 30, 2026, and disclosing a new investor presentation posted the same day.
Cadre Holdings, Inc. filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on November 4, 2026, announcing its financial results for the quarter ended September 30, 2026.
Sight Sciences, Inc. filed a Form 8-K with the SEC on November 4, 2026, reporting its financial results for the quarter ended September 30, 2026, and announcing an upward revision to its full-year 2026 revenue guidance.
Texas Pacific Land Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting nine-month net income of $464.2 million and third-quarter net income of $167.4 million.
Voya Financial, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting condensed consolidated financial statements and related disclosures.
Lyell Immunopharma, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 30, 2026.
The ONE Group Hospitality, Inc. filed its Form 10-Q for the quarterly period ended September 27, 2026, with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a net loss of $15,745 thousand for the nine periods ended September 27, 2026.
The Allstate Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 4, 2026, reporting third-quarter net income of $2.080 billion and total revenues of $17.348 billion.
Jim Wassil, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Vaxcyte, Inc., filed a Form 4 on November 4, 2026, disclosing a stock option exercise and two open-market sales of common stock executed on November 2, 2026, under a pre-established Rule …